药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Sulfapyridine
Sodium aurothiomalate
The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Spirapril is combined with Sodium aurothiomalate.
Sulfapyridine
Tolvaptan
Tolvaptan may increase the hyperkalemic activities of Spirapril.
Sulfapyridine
Lithium hydroxide
The serum concentration of Lithium hydroxide can be increased when it is combined with Spirapril.
Sulfapyridine
Lithium carbonate
The serum concentration of Lithium carbonate can be increased when it is combined with Spirapril.
Sulfapyridine
Lithium citrate
The serum concentration of Lithium citrate can be increased when it is combined with Spirapril.
Sulfapyridine
Icatibant
Icatibant may decrease the antihypertensive activities of Spirapril.
Sulfapyridine
Semuloparin
The risk or severity of hyperkalemia can be increased when Spirapril is combined with Semuloparin.
Sulfapyridine
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.
Sulfapyridine
Drospirenone
Spirapril may increase the hyperkalemic activities of Drospirenone.
Sulfapyridine
Dapoxetine
Dapoxetine may increase the orthostatic hypotensive activities of Spirapril.
Sulfapyridine
Empagliflozin
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Spirapril.
Sulfapyridine
Dapagliflozin
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Spirapril.
Sulfapyridine
Canagliflozin
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Spirapril is combined with Canagliflozin.
Sulfapyridine
Ertugliflozin
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ertugliflozin is combined with Spirapril.
Sulfapyridine
Aprotinin
Aprotinin may decrease the antihypertensive activities of Spirapril.
Sulfapyridine
Aliskiren
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Spirapril.
Sulfapyridine
Naxitamab
Naxitamab may decrease the antihypertensive activities of Spirapril.
Sulfapyridine
Selpercatinib
Selpercatinib may decrease the antihypertensive activities of Spirapril.
Sulfapyridine
Moxonidine
Moxonidine may decrease the antihypertensive activities of Spirapril.
Sulfapyridine
Indoramin
Indoramin may decrease the antihypertensive activities of Spirapril.